PLSE — Pulse Biosciences Share News
0.000.00%
Last trade - 00:00- $1.97bn
- $1.90bn
- $0.35m
Brief: Pulse Biosciences Announces FDA IDE Approval To Initiate Its nsPFA Cardiac Surgery System Study For The Treatment Of Atrial Fibrillation
Pulse Biosciences rises on FDA approval to test its heart device
Pulse Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Pulse Biosciences Q2 EPS USD -0.28
Pulse Biosciences Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: Pulse Biosciences Q1 EPS USD -0.25
Brief: Pulse Biosciences Q4 EPS USD -0.31
Brief: Pulse Biosciences Appoints Jon Skinner As Chief Financial Officer
Brief: Pulse Biosciences Announces Planned Redemption Of Warrants
Brief: Pulse Biosciences Q3 EPS USD -0.21
Brief: Pulse Biosciences Appoints Paul Laviolette To Its Board
Brief: Pulse Biosciences Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation
Brief: Pulse Biosciences Announces The Closing Of Its Rights Offering
Brief: Pulse Biosciences Announces Preliminary Results For Its Rights Offering
Brief: Pulse Biosciences Q1 EPS USD -0.18
Brief: Pulse Biosciences Inc Files For Mixed Shelf Of Up To $50 Million - SEC Filing
Brief: Pulse Biosciences Announces Plans To Initiate A Rights Offering
Brief: Pulse Biosciences Q4 EPS USD -0.22
Brief: Pulse Biosciences First-In-Human Procedures With Its Novel Cellfx™ Nanosecond Pulsed Field Ablation (Nspfa™) Cardiac Catheter